Skip to main content
Log in

Individual Differences of Multipotent Mesenchymal Stromal Cells Manifesting in during Interaction with Lymphocytes

  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Analysis of changes in lymphocyte subpopulations during co-culturing with multipotent mesenchymal stromal cells (MSC) revealed two distinct MSC groups: one group (A) increased HLA-DR expression on lymphocytes during co-culturing and the other (B) did not change it in comparison with lymphocyte monoculture. In stromal cells interacting with lymphocytes, expression of HLA-DR molecules was initiated, but only in samples that induced enhanced expression on lymphocytes and irrespectively of whether allogeneic or autologous lymphocytes were used for co-culturing with MSC. In group A, the relative expression of IDO1 significantly increased in comparison with group B. The revealed individual differences in MSC can explain why not all MSC samples are effective in the treatment of autoimmune diseases, acute “graft—versus—host” disease, and other pathologies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005; 105(4):1815-1822.

    Article  PubMed  CAS  Google Scholar 

  2. Castro-Manrreza ME, Montesinos JJ. Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J. Immunol. Res. 2015;2015. ID 394917. doi: https://doi.org/10.1155/2015/394917.

  3. Jones BJ, McTaggart SJ. Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp. Hematol. 2008; 36(6):733-741.

    Article  PubMed  CAS  Google Scholar 

  4. Kapranov NM, Davydova YO, Galtseva IV, Petinati NA, Drize NI, Kuzmina LA, Parovichnikova EN, Savchenko VG. Effect of priming of multipotent mesenchymal stromal cells with interferon g on their immunomodulating properties. Biochemistry (Mosc). 2017;82(10):1158-1168.

    Article  PubMed  CAS  Google Scholar 

  5. Kapranov NM, Davydova JuO, Petinati NA, Bakshinskayte MV, Galtseva IV, Drize NI, Kuzmina LA, Parovichnikova EN, Savchenko VG. Alterations in multipotent mesenchymal stromal cells properties: in vitro model of their interactions with allogeneic lymphocytes. Cell. Ther. Transplant. 2016;5(3):39-41.

    Article  Google Scholar 

  6. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V, Mazzinghi B, Pizzolo G, Vinante F, Romagnani P, Maggi E, Romagnani S, Annunziato F. Role for interferon-g in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24(2):386-398.

    Article  PubMed  CAS  Google Scholar 

  7. Le Blanc K, Rasmusson I, Götherström C, Seidel C, Sundberg B, Sundin M, Rosendahl K, Tammik C, Ringdén O. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand. J. Immunol. 2004;60(3):307-315.

    Article  PubMed  Google Scholar 

  8. Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who’s who of T-cell differentiation: Human memory T-cell subsets. Eur. J. Immunol. 2013;43(11):2797-2809.

    Article  PubMed  CAS  Google Scholar 

  9. Petinati NA, Kapranov NM, Bigil’deev AE, Popova MD, Davydova YO, Gal’tseva IV, Drize NI, Kuz’mina LA, Parovichnikova EN, Savchenko VG. Changing the properties of multipotent mesenchymal stromal cells by IFNg administration. Bull. Exp. Biol. Med. 2017;163(2):230-234.

    Article  PubMed  CAS  Google Scholar 

  10. Petinati N, Shipounova I, Sats N, Bigildeev A, Drize N, Kuzmina L, Parovichnikova E, Savchenko V. Alterations between effective and ineffective multipotent mesenchymal stromal cells used for acute graft versus host disease prophylaxis. Med. Res. Arch. 2016;4(1):1-22.

    Google Scholar 

  11. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C (T) method. Nat. Protoc. 2008;3(6):1101-1108.

    Article  PubMed  CAS  Google Scholar 

  12. Wang M, Windgassen D, Papoutsakis ET. Comparative analysis of transcriptional profiling of CD3+, CD4+ and CD8+ T cells identifies novel immune response players in T-cell activation. BMC Genomics. 2008;9:225. doi: https://doi.org/10.1186/1471-2164-9-225.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to N. I. Drize.

Additional information

Translated from Kletochnye Tekhnologii v Biologii i Meditsine, No. 2, pp. 129-134, June, 2018

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kapranov, N.M., Davydova, Y.O., Gal’tseva, I.V. et al. Individual Differences of Multipotent Mesenchymal Stromal Cells Manifesting in during Interaction with Lymphocytes. Bull Exp Biol Med 165, 584–588 (2018). https://doi.org/10.1007/s10517-018-4218-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10517-018-4218-3

Key Words

Navigation